CAMBRIDGE, Mass. – Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced today the appointment of Howard Liang, Ph.D., as President and Chief Financial Officer. The company also expanded its executive bench with newly promoted talent and hires: Madhusudan Peshwa, Ph.D., as Chief Technology Officer for...
Latest News
Leena Bruckner-Tuderman from the Department of Dermatology at the University Medical Centre in Freiburg has just been awarded the Eva Luise Köhler Research Prize for Rare Diseases. She has not only made a decisive contribution to the clarification of the molecular causes of the skin disease “dystrophic epidermolysis bullosa”, but...
SOMERSET, N.J. — Legend Biotech Co. (NASDAQ: LEGN), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have...
SOMERSET, N.J. – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of ciltacabtagene...
Klosterneuburg, Austria – At school, he was inspired by Schrödinger´s book ‘What is Life?’. Now, several decades later, Leonid Sazanov is awarded the Erwin Schrödinger Prize by the Austrian Academy of Sciences (ÖAW). The scientist heads a research group at the Institute of Science and Technology Austria (ISTA) and was...
STOCKHOLM, Sweden — BioArctic AB’s partner Eisai announced today that Leqembi® (brand name in China: “乐意保”, generic name: lecanemab-irmb) has been approved in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to grant marketing approval,...
NEW YORK, NY — LEXEO Therapeutics Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company’s AAVrh.10hFXN-based gene therapy candidate...
THE WOODLANDS, Texas – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney...
Wayne, N.J.— Life Raft Group (LRG), the pre-eminent patient-based organization dedicated to finding a cure for a deadly cancer called gastrointestinal stromal tumors (GIST), today announced the launch of the GIST Collaborative Tissue Bank, a partnership between twelve internationally-renowned GIST researchers and the Life Raft Group, whose Patient Registry houses...
EMERYVILLE, Calif. – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458. Rylaze, which was approved by the FDA on June 30, 2021, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for...